Anti-apoptotic proteins-targets for chemosensitization of tumor cells and cancer treatment

Neoplasma

Volumn 52, Issue 6, 2005, Pages 441-449

  Kostanova Poliakova D ^a   Sabova L ^a  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

Antisense oligonucleotides; Apoptosis; Bcl 2 protein family; BH3 mimetics; BH3 peptides; Cancer; Chemoresistance

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE G3139; APOPTOSIS INHIBITOR; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; GEMTUZUMAB OZOGAMICIN; OXALIPLATIN; PROTEIN BCL 2; PROTEIN BCL XL; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER SURGERY; CELL FUNCTION; CELL KILLING; CELL MATURATION; CELL PROTECTION; CLINICAL TRIAL; HUMAN; INHIBITION KINETICS; META ANALYSIS; PROTEIN TARGETING; REGULATORY MECHANISM; SHORT SURVEY; SYSTEMATIC REVIEW; TUMOR CELL CULTURE;

EID: 29144514385     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (83)

1. ADAMS JM, CORY S. The Bcl-2 protein family: Arbiters of cell survival. Science 1998; 281: 1322-1326.
2. ANTONSSON B, MARTINOU JC. The bcl-2 protein family. Exp Cell Res 2000; 256: 50-57.
3. ANTONSSON B. Bax and other pro-apoptotic Bcl-2 family "killer proteins" and their victim, the mitochondrion. Cell Tissue Res 2001; 306: 347-361.
4. ASHKENAZI A, DIXIT VM. Death receptors: signaling and modulation. Science 1998; 281: 1305-1308.
5. BECATTINI B, KITADA S, LEONE M, MONOSOV E, CHANDLER S et al. Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). Chem Biol 2004; 11: 389-395.
6. BERDEN JA, SLATER EC. The allosteric binding of antimycin to cytochrome b in the mitochondrial membrane. Biochim Biophys Acta 1972; 256: 199-215.
7. CARTRON PF, GALLENNE T, BOUGRAS G, GAUTIER F, MANERO F et al. The first alpha helix of Bax plays a necessary role in its ligand-induced activation by the BH3-only proteins Bid and PUMA. Mol Cell 2004; 16: 807-818.
8. CHAN SL, LEE MCH, TAN KO, YANG LK, LEE ASY et al. Identification of chelerythrine as an inhibitor of BclXL function. J Biol Chem 2003; 278: 20453-20456.
9. CHEN L, WILLIS SN, WEI A, SMITH BJ, FLETCHER JI et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393-403.
10. CHI KN, GLEAVE ME, KLASA R, MURRAY N, BRYCE C et al. A phase I dose finding study combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 2001; 7: 3920-3927.
11. CORY S, HUANG DCS, ADAMS JM. The Bcl-2 family: roles in survival and oncogenesis. Oncogene 2003; 22: 8590-8607.
12. COTTER FE, JOHNSON P, HALL P, POCOCK C, AL HAHDI N et al. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 1994; 10: 3049-3055.
13. CROOKE ST. Therapeutic application of oligonucleotides. Annu Rev Pharmacol Toxicol 1992; 32: 329-376.
14. CRYNS V, YUAN J. Proteases to die for. Genes Dev 1998; 12: 1551-1570.
15. DEGTEREV A, LUGOVSKOY A, CARDONE M, MULLEY B, WAGNER G et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nature Cell Biol 2001; 3: 173-182.
16. GROSS A, MCDONNELL JM, KORSMEYER SJ. Bcl-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13: 1899-1911.
17. HAO JH, YU M, LIU FT, NEWLAND AC, JIA L. Bcl-2 inhibitors sensitize tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by uncoupling of mitochondrial respiration in human leukemic CEM cells. Cancer Res 2004; 64: 3607-3616.
18. HARADA H, QUEARRY B, RUIZ-VELA A, KORSMEYER SJ. Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proc Natl Acad Sci USA 2004; 101: 15313-15317.
19. HAUSMANN G, O'REILLY LA, VAN DRIEL R, BEAUMONT JG, STRASSER A et al. Pro-apoptotic apoptosis protease-activating factor 1 (Apaf-1) has a cytoplasmic localization distinct from Bcl-2 or Bcl-x(L). J Cell Biol 2000; 149: 623-634.
20. HAYWARD RL, MACPHERSON JS, CUMMINGS J, MONIA BP, SMYTH JF, JODRELL DI. Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect. Mol Cancer Ther 2004; 2: 169-178.
21. HERBERT JM, AUGEREAU JM, GLEYE J, MAFFRAND JP. Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochim Biophys Res Commun 1990; 172: 993-999.
22. HERR I, DEBATIN KM. Cellular stress response and apoptosis in cancer therapy. Blood 2001; 98: 2603-2614.
23. HERWEIJER H, WOLFF JA. Progress and prospects: naked DNA gene transfer and therapy. Gene Ther 2003; 6: 453-458.
24. HINDS MG, LACKMANN M, SKEA GL, HARRISON PJ, HUANG DCS, DAY CL. The structure of Bcl-w reveals a role for the C-terminal residues in modulating biological activity. EMBO J 2003; 22: 1497-1507.
25. 2-terminal BH4 domain of Bcl-2 is functional for heterodimerization with Bax and inhibition of apoptosis. J Biol Chem 1999; 274: 20415-20420.
26. XL function and induce apoptosis through cytochrome c-independent activation of caspases. J Biol Chem 1999; 274: 13298-13304.
27. HSU YT, WOLTER KG, YOULE RJ. Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Proc Natl Acad Sci USA 1997; 94: 3668-3672.
28. HUANG DC, TSCHOPP J, STRASSER A. Bcl-2 does not inhibit cell death induced by the physiological FAS ligand: implication for the existence of type I and type II cells. Cell Death Differ 2000; 8: 754-755.
29. HUANG DCS, STRASSER A. BH3-only proteins-essential initiators of apoptotic cell death. Cell 2000; 103: 839-842.
30. JANIAK F, LEBER B, ANDREWS DW. Assembly of Bcl-2 into microsomal and outer mitochondrial membranes. J Biol Chem 1994; 269: 9842-9849.
31. JANSEN B, SHLAGBAUER-WADL H, BROWN BD, BRYAN RN, VAN ELSAS A et al. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998; 2: 232-234.
32. JOHNSTONE RW, RUEFLI AA, LOWE SW. Apoptosis: A link between cancer genetics and chemotherapy. Cell 2002; 108: 153-164.
33. XL. Mol Cell Biol 1997; 17: 7040-7046.
34. KITADA S, MIYASHITA T, TANAKA S, REED JC. Investigations of antisense oligonucleotides targeted against bcl-2 RNAs. Antisense Res Dev 1993; 2: 157-169.
35. KITADA S, TAKAYAMA S, DERIEL K, TANAKA S, REED JC. Reversal of chemoresistence of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev 1994; 2: 71-79.
36. KUWANA T, BOUCHER-HAYES L, CHIPUK JE, BONZON CH, SULLIVAN BA et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005; 17: 525-535.
37. LAPPALAINEN K, URTTI A, SODERLING E, JAASKELAINEN I, SYRJANEN K, SYRJANEN S. Cationic liposomes improve stability and intracellular delivery of antisense oligonucleotides into CaSki cells. Biochim Biophys Acta 1994; 1196: 201-208.
38. LEBEDEVA I, RANDO R, OJWANG J, COSSUM P, STEIN CA. Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Res 2000; 60: 6052-6060.
39. LEECH SH, OLIE RA, GAUTCHI O, SIMONES-WUST AP, TSCHOP S et al. Induction of apoptosis in lung-cancer cells following bcl-XL anti-sense treatment. Int J Cancer 2000; 86: 570-576.
40. LI LY, LUO X, WANG X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 2001; 412: 95-99.
41. LI P, NIJHAWAN D, BUDIHARDJO I, SRINIVASULA SM, AHMAD M et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase complex initiates an apoptotic protease cascade. Cell 1997; 91: 479-489.
42. LIU D, HUANG Z. Synthetic peptides and non-peptidic molecules as probes of structure and function of Bcl-2 family proteins and modulators of apoptosis. Apoptosis 2001; 6: 453-462.
43. LUO X, BUDIHARDJO I, ZHOU H, SLAUGHTER C, WANG X. Bid, a Bcl-2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94: 481-490.
44. MONIA BP, LESNIK EA, GONZALES C, LIMA WF, MCGEE D et al. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 1993; 268: 14514-14522.
45. MORIMOTO M, FUKUI M, OHKUBO S, TAMAOKI T, TOMOTA F. Tetrocarcins, new antitumor antibiotics. III. Antitumor activity of tetrocarcin A. J Antibiot 1982; 35: 1033-1037.
46. MOREAU C, CARTRON PF, HUNT A, MEFLAH K, GREEN DR et al. Minimal BH3 peptides promote cell death by antagonizing anti-apoptotic proteins. J Biol Chem 2003; 278: 19426-19435.
47. MUCHMORE SW, SATTLER M, LIANG H, MEADOWS RP, HARLAN JE et al. X-ray and NMR structure of human Bcl-xL an inhibitor of programmed cell death. Nature 1996; 381: 335-341.
48. NAGATA S. Apoptosis by death factor. Cell 1997; 88: 355-365.
49. NAKASHIMA T, MIURA M, KARA M. Tetrocarcin A inhibits mitochondrial functions of Bcl-2 and suppresses its anti-apototic activity. Cancer Res 2000; 60: 1229-1235.
50. NGUYEN M, MILLAR DG, YONG VW, KORSMEYER SJ, SHORE GC. Targeting of Bcl-2 to the mitochondrial outer membrane by a COOH-terminal signal anchor sequence. J Biol Chem 1993; 268: 25265-25268.
51. OLIVER CL, BAUER JA, WOLTER KG, UBELL ML, NARAYAN A et al. In vitro effect of the BH3 mimetic, (-)- gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res 2004; 10: 7757-7763.
52. OLTVAI ZN, MILLIMAN CL, KORSMEYER SJ. Bcl-2 heterodimerizes in vivo with conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-619.
53. O'REILLY LA, PRINT C, HAUSMANN G, MORIISHI K, CORY S et al. Tissue expression and subcellular localization of the pro-survival molecule Bcl-w. Cell Death Differ 2001; 8: 486-494.
54. OZVARAN MK, CAO XX, MILLER SD, MONIA BA, HONG WK, SMYTHE WR. Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma. Mol Cancer Ther 2004; 5: 545-450.
55. PETROS AM, MEDEK A, NETTESHEIM DG, KIM DH, YOON HS et al. Solution structure of the antiapoptotic protein Bcl-2. Proc Natl Acad Sci USA 2001; 98: 3012-3017.
56. RAYNAUD FI, ORR RM, GODDARD PM, LACEY HA, LANCASHIRE H et al. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther 1997; 281: 420-427.
57. RUDIN CM, KOZLOFF M, HOFFMAN PC, EDELMAN MJ, KARNAUSKAS R et al. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 2004; 6: 1110-1117.
58. RUDIN CM, OTTERSON GA, MAUER AM, VILLALONA-CALERO MA, TOMEK R et al. A pilot trial of G3139, a bcl-2 oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 2002; 4: 501-502.
59. SATTLER M, LIANG H, NETTESHEIM D, MEADOWS RP, HARLAN JE et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997; 275: 983-986.
60. SCAFFIDI C, FULDA S, SRINIVASAN A, FRIESEN C, Li F et al. Two CD95 (APO-1/FAS) signaling pathways. EMBO J 1998; 17: 1675-1687.
61. SCHMITZ I, KIRCHHOFF S, KRAMMER PH. Regulation of death receptor-mediated apoptosis pathways. Int J Biochem Cell Biol 2000; 32: 1123-1136.
62. XL antisense treatment induces apoptosis in breast carcinoma cells. Int J Cancer 2000; 87: 582-590.
63. STEIN CA, SUBASINGHE C, SHINOZUKA K, COHEN JS. Physiochemical properties of phosphorothioate oligonucleotides. Nucl Acid Res 1998; 16: 3209-3221.
64. SUSIN SA, LORENZO HK, ZAMZAMI N, MARZO I, SNOW BE et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999; 397: 441-446.
65. SUZUKI Y, IMAI Y, NAKAYAMA H, TAKAHASHI K, TAKIO K, TAKAHASHI R. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol Cell 2001; 8: 613-621.
66. TAMAOKI T, KASAI M, SHIRAHATA K, OHKUBO S, MORIMOTO M et al. Tetrocarcins, novel antitumor antibiotics. II. Isolation, characterization and antitumor activity. J Antibiot 1980; 33: 946-950.
67. THOMPSON CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-1462.
68. THORNBERRY N, LAZEBNIK Y. Caspases: enemies within. Science 1998; 281: 1312-1316.
69. TYSZYNSKI GP, COSSU G. Differential cytotoxic effect of gossypol on human melanoma, colon carcinoma and other tissue culture cell lines. Cancer Res 1984; 44: 768-772.
70. TZUNG SP, KIM KM, BASANEZ G, GIEDT CHD, SIMON J et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nature Cell Biol 2001; 3: 183-191.
71. VAN POZNAK C, SEIDMAN AD, REIDENBERG MM, MOASSER MM, SKLARIN N et al. Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial. Breast Cancer Res Treat 2001; 66: 239-248.
72. VERHAGEN AM, EKERT PG, PAKUSCH M, SILKE J, CONNOLLY LM et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000; 102: 43-53.
73. WALENSKY LD, KUNG AL, ESCHER I, MALLATJ, BARBUTO S et al. Activation of apoptosis in vivo by a hydrocarbon-stapeled BH3 helix. Science 2004; 305: 1466-1470.
74. WANG JL, LIU D, ZHANG ZJ, SHAN S, HAN X et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 2000; 97: 7124-7129.
75. WANG JL, ZHANG ZJ, CHOKSI S, SHAN S, LU Z et al. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res 2000; 60: 1498-1502.
76. WATERS JS, WEBB A, CUNNINGHAM D, CLARKE PA, RAYNAUD F et al. Phase I clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-Hodkin's lymphoma. J Clin Oncol 2000; 18: 1812-1823.
77. WILSON-ANNAN J, O'REILLY LA, CRAWFORD SA, HAUSMANN G, BEAUMONT JG et al. Proapoptotic BHS-only proteins trigger membrane integration of prosurvival Bcl-w and neutralize its activity. J Cell Biol 2003; 162: 877-887.
78. ZANGEMEISTER-WITTKE U, SCHENKER T, LUEDKE GH, STAHEL RA. Synergistic cytotoxicity of bcl-2 antisense oligonucleotides and etoposide, doxorubicin and cisplatin on small-cell cancer cell lines. Br J Cancer 1998; 78: 1034-1042.
79. XL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res 2000; 6: 2547-2555.
80. ZHA H, AIME-SEMPE C, SATO T, REED JC. Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2. J Biol Chem 1996; 271: 7440-7444.
81. ZHANG M, LIU H, GUO R, LING Y, WU X et al. Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem Pharmacol 2003; 66: 93-103.
82. ZIEGLER A, LUEDKE GH, FABBRO D, ALTMANN KH, STAHEL RA. Induction of apoptosis in small-cell lung cancer cells by an antisense oligonucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst 1997; 89: 988-990.
83. ZOU H, LI Y, LIU X, WANG X. An APAF-1 cytochrome c multimeric complex is functional apoptosome that activates pro-caspase 9. J Biol Chem 1999; 274: 11549-11554.